Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | M Favata, K Lasky, Y Lo, P Feldman, J Li, Y Chen, C Stevens, M Ye, H Wang, K Liu, R Wynn, Yanlon Li, J Harris, R Landman, Y Li, X Wang, C He, Y Li, C Xue, W Yao, J Rios-Doria, Z Gao, M Covington, XM Liu, H Koblish and P Scherle | ||||||||||||
Title | Characterization of INCB081776, a potent and selective dual AXL/MER kinase inhibitor | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/78/13_Supplement/3759 | ||||||||||||
Abstract Text | Cancer Res 2018;78(13 Suppl):Abstract nr 3759 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
INCB081776 | INCB081776 | 0 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INCB081776 | INCB-081776 | AXL Inhibitor 29 | INCB081776 is a dual inhibitor of Axl and Mer that blocks TAM family kinase signaling, which may results in enhanced anti-tumor immunity (Cancer Res 2018;78(13 Suppl):Abstract nr 3759). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|